MK-677 (Ibutamoren): The Oral Growth Hormone Secretagogue
The only orally active ghrelin mimetic with multi-year clinical data. What it actually does to GH, IGF-1, body composition, and sleep, plus the insulin resistance problem nobody wants to talk about.
in 12-Month RCT
IGF-1 Levels
(Young Adults)
Participants (AD)
MK-677 (ibutamoren) occupies a unique position in the peptide and performance-enhancement space. It's not technically a peptide; it's a small molecule that mimics the hunger hormone ghrelin. It's not a SARM, despite being sold alongside them. And it's not FDA-approved for anything, despite having more controlled clinical trial data than most compounds in this space.
What makes MK-677 genuinely interesting is its mechanism: oral administration that produces sustained, pulsatile growth hormone release matching the body's natural secretion pattern. No injections. No reconstitution. No cold chain storage. Just a pill that reliably raises GH and IGF-1 levels, with all the benefits and all the metabolic consequences that entails.
MK-677 reliably increases GH and IGF-1 levels. The hormonal data is unambiguous. But hormonal changes ≠ clinical outcomes. The largest and longest RCT (65 subjects, 2 years) found increased fat-free mass but no improvement in strength, physical function, or quality of life. Meanwhile, fasting glucose rose and insulin sensitivity declined. The gap between "raised my IGF-1" and "made me measurably stronger/healthier" is where most MK-677 marketing falls apart.
What MK-677 Actually Is
MK-677 / Ibutamoren Mesylate
Type: Non-peptide ghrelin receptor agonist (growth hormone secretagogue) | Molecular Weight: 528.67 g/mol | Developer: Merck Research Laboratories | Route: Oral | Half-life: ~24 hours | Clinical Status: Investigational (Phase II completed); not FDA-approved | Also Known As: Ibutamoren, MK-0677, L-163,191, LUM-201 | Sport Status: Prohibited at all times (WADA 2025)
MK-677 was developed by Merck Research Laboratories in the early 1990s as part of a program to create orally active growth hormone secretagogues. The goal was simple: find a molecule that could stimulate the body's own growth hormone production through a pill, potentially replacing expensive daily GH injections for patients with GH deficiency, muscle wasting, and age-related frailty.
The compound works by mimicking ghrelin, the 28-amino-acid "hunger hormone" that the stomach produces when empty. Ghrelin binds to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary gland, triggering growth hormone release. MK-677 does the same thing, but with several pharmacological advantages over ghrelin itself:
Oral Bioavailability
Native ghrelin degrades rapidly in the GI tract. MK-677 is a non-peptide small molecule that survives oral administration intact, making it the only orally active ghrelin mimetic with significant clinical data.
Extended Half-Life
Ghrelin has a half-life of about 30 minutes. MK-677's half-life is approximately 24 hours, enabling once-daily dosing with sustained GH elevation throughout the circadian cycle.
Preserved Pulsatility
Unlike exogenous GH injection (which creates a single unnatural spike), MK-677 preserves the body's natural pulsatile GH secretion pattern, amplifying pulse amplitude rather than overriding the system.
No HPG Axis Suppression
MK-677 does not suppress testosterone, LH, FSH, or other reproductive hormones. No post-cycle therapy (PCT) is required, a significant advantage over SARMs and anabolic steroids.
MK-677 is frequently categorized with peptides and SARMs on vendor sites, but it is neither. It's a non-peptide small molecule, closer in structure to a traditional pharmaceutical drug than to BPC-157 or CJC-1295. It doesn't bind androgen receptors (making it not a SARM) and it isn't a chain of amino acids (making it not a peptide). This distinction matters for understanding its pharmacology, safety profile, and regulatory status.
Mechanism of Action: How MK-677 Works
When MK-677 binds to the GHS-R1a receptor, it triggers a signaling cascade through the hypothalamic-pituitary axis. The key distinction from exogenous GH injection: MK-677 amplifies the body's own GH pulses rather than creating artificial hormone spikes. A 1996 study by Copinschi et al. demonstrated that 7 days of bedtime MK-677 (25 mg) in healthy young men enhanced 24-hour GH profiles by increasing the amplitude of existing secretory pulses (not their frequency), preserving the natural circadian GH rhythm.
This preserved pulsatility matters because the body's tissues respond differently to pulsatile vs. continuous GH exposure. The liver produces IGF-1 in response to GH pulses, and muscle, bone, and connective tissues rely on the rhythmic fluctuation of GH for optimal anabolic signaling. When you inject GH directly, you bypass this pulsatile system. MK-677 works with it.
The Ghrelin Connection: More Than Just Growth Hormone
Because MK-677 activates ghrelin receptors, its effects extend beyond GH release. The GHS-R1a receptor is expressed not just in the pituitary but also in the hypothalamus (appetite regulation), hippocampus (memory), and brainstem (sleep-wake regulation). This broad receptor distribution explains why MK-677 affects appetite, sleep architecture, and potentially cognition, not just growth hormone levels.
Human Clinical Evidence: What the Studies Actually Show
MK-677 has more controlled human clinical data than most compounds discussed in the peptide community. Merck sponsored multiple Phase II trials through the late 1990s and 2000s. Here's what they found, both the impressive parts and the disappointing parts.
1. Body Composition (Nass et al., 2008, The Landmark Trial)
The largest and longest MK-677 body composition study enrolled 65 healthy older adults (60-81 years) in a 2-year randomized, double-blind, placebo-controlled trial at the University of Virginia. Subjects received 25 mg MK-677 or placebo daily.
| Endpoint | MK-677 (12 months) | Placebo (12 months) | Significance |
|---|---|---|---|
| Fat-free mass (FFM) | +1.1 kg (0.7 to 1.5) | −0.5 kg (−1.1 to 0.2) | P < 0.001 |
| 24h mean GH | Restored to young-adult levels | No change | P < 0.001 |
| Serum IGF-1 | Elevated to young-adult range | No change | P < 0.001 |
| Isokinetic strength | No improvement | No change | Not significant |
| Physical function | No improvement | No change | Not significant |
| Quality of life | No improvement | No change | Not significant |
| Abdominal visceral fat | No significant change | No change | Not significant |
| Fasting glucose | Increased ~5 mg/dL | Slight decrease | HbA1c +0.2% vs placebo |
| Body weight | Increased (water + lean) | Stable | P < 0.05 |
MK-677 reliably increased GH and IGF-1 to young-adult levels and produced a statistically significant increase in fat-free mass. But it did not improve strength, physical function, or quality of life. Some of the FFM increase may reflect intracellular water rather than new contractile muscle tissue, a known confounder with GH-axis modulation. This study is the best evidence available, and it tells a nuanced story: the hormonal effects are real, but they don't automatically translate into meaningful performance or health outcomes.
2. Anti-Catabolism (Murphy et al., 1998)
In a study of healthy young adults placed on a calorie-restricted diet designed to induce protein catabolism, MK-677 (25 mg daily for 7 days) significantly reversed the nitrogen-wasting effect. Peak GH response was 55.9 μg/L after the first dose (vs. ~9 μg/L placebo), and IGF-1 levels increased from diet-suppressed levels of 186 to 264 ng/mL. This study established MK-677's potential for muscle-sparing during caloric restriction, relevant for both clinical wasting conditions and dieting athletes.
3. Sleep Architecture (Copinschi et al., 1997)
A double-blind, placebo-controlled crossover study examined MK-677's effects on polysomnographically measured sleep in 8 young adults (18-30) and 6 older adults (65-71). The results were striking:
Young Adults (25 mg, 7 days)
Stage IV (deep) sleep increased by ~50%. REM sleep duration was also increased. Overall sleep quality improved as measured by reduced deviations from normal sleep patterns. This is one of the most consistent and well-replicated effects of MK-677.
Older Adults (25 mg, 14 days)
REM sleep increased by ~20%. Older subjects showed improvement in sleep efficiency and architecture. The effects were dose-dependent; higher doses produced more pronounced sleep changes. Participants reported feeling more refreshed upon waking.
MK-677's sleep effects may be its most clinically relevant finding. Growth hormone is predominantly secreted during slow-wave sleep, and GH secretion declines with age partly because deep sleep declines. By improving sleep architecture, MK-677 may create a positive feedback loop: better sleep → more natural GH secretion → better sleep quality. For users who report the most dramatic subjective benefits from MK-677, improved sleep is frequently the primary driver, and better sleep cascades into improved recovery, mood, and cognitive function.
4. Bone Metabolism (Murphy et al., 1998-2001)
Multiple studies examined MK-677's effects on bone turnover markers. In 24 obese young males, 8 weeks of MK-677 produced a 23% increase in the bone formation marker PICP, a 28% increase in procollagen III, and a 15% increase in osteocalcin by week 8. Bone resorption markers also increased, indicating accelerated bone remodeling, consistent with GH/IGF-1 effects. A separate study in postmenopausal osteoporotic women found that MK-677 combined with alendronate produced additive bone marker changes. However, these were short-term marker studies; actual bone mineral density improvements require longer observation periods.
5. Obese Subjects (Svensson et al., 1998)
A 2-month, double-blind, placebo-controlled trial in 24 obese men found that MK-677 increased GH secretion, fat-free mass, and basal metabolic rate. The BMR increase was transient. Fat mass did not significantly decrease. This study is often cited as evidence for MK-677's "fat burning" properties, but the data is more modest than the marketing suggests. The primary body composition change was lean mass gain (partly water-mediated), not meaningful fat loss.
6. Alzheimer's Disease (Sevigny et al., 2008, Largest MK-677 Trial)
The largest MK-677 trial ever conducted randomized 563 patients with mild-to-moderate Alzheimer's disease to 25 mg MK-677 or placebo daily for 12 months. The rationale: IGF-1 clears beta-amyloid in animal models, so raising IGF-1 might slow AD progression. MK-677 successfully increased IGF-1 by 60% at 6 weeks and 73% at 12 months. However, there was no improvement in any cognitive or functional outcome measure. Despite clear target engagement, elevated IGF-1 did not translate into clinical benefit.
7. GH-Deficient Children (Codner et al., 2001)
MK-677 was tested in children with growth hormone deficiency, where it successfully increased GH, IGF-1, and IGFBP-3 levels without altering prolactin, glucose, thyroid hormones, cortisol, or insulin concentrations. This suggested a potentially cleaner metabolic profile in younger, GH-deficient populations compared to elderly subjects, though this indication has been developed further under the name LUM-201 by Lumos Pharma, which completed Phase II trials in pediatric GHD.
Complete Clinical Evidence Summary
| Study | N | Population | Duration | Key Findings | Limitations |
|---|---|---|---|---|---|
| Nass et al., 2008 | 65 | Healthy elderly | 2 years | +1.1 kg FFM; GH/IGF-1 restored; no strength gain; glucose ↑ | Underpowered for functional endpoints |
| Murphy et al., 1998 | 32 | Healthy young (cal. restricted) | 7 days | Reversed nitrogen wasting; IGF-1 ↑ to 264 ng/mL | Very short duration |
| Copinschi et al., 1997 | 14 | Young + older adults | 7-14 days | Deep sleep +50% (young); REM +20% (older) | Small sample; short-term |
| Svensson et al., 1998 | 24 | Obese men | 2 months | ↑ FFM, ↑ BMR (transient), GH ↑ | No significant fat loss |
| Murphy et al., 1998 | 24 | Obese young males | 8 weeks | Bone formation markers ↑ 23-28% | Markers only, no BMD data |
| Sevigny et al., 2008 | 563 | Alzheimer's patients | 12 months | IGF-1 ↑ 73%; zero cognitive improvement | AD population; different aim |
| Codner et al., 2001 | 18 | GH-deficient children | 7 days | GH/IGF-1 ↑ without metabolic disruption | Very small; very short |
Evidence-Graded Benefits
Not all claimed MK-677 benefits have equal evidence behind them. Here's an honest grading:
| Claimed Benefit | Evidence Grade | What Data Actually Shows |
|---|---|---|
| Increases GH and IGF-1 | Strong (multiple RCTs) | Consistent 40-97% GH increase and 60-73% IGF-1 increase across all trials |
| Improves sleep quality | Moderate-Strong (RCT) | Polysomnographic evidence of increased deep sleep and REM; one of the most consistently reported subjective benefits |
| Increases fat-free mass | Moderate (RCT data) | +1.1 kg in 12 months; unclear how much is contractile muscle vs. intracellular water |
| Anti-catabolic (muscle sparing) | Moderate (short study) | Reversed diet-induced catabolism in one 7-day trial; promising but minimal data |
| Increases bone turnover | Moderate (markers) | Formation and resorption markers both increase; actual BMD changes unconfirmed |
| Improves body composition | Weak-Moderate | Lean mass up, but fat mass not reduced; no meaningful visceral fat change in 2-year study |
| Increases muscle strength | Weak (failed in RCT) | No strength improvement in the longest/largest body composition trial |
| Cognitive enhancement | Negative (large trial) | 563-patient AD trial showed zero cognitive benefit despite 73% IGF-1 increase |
| Fat burning / weight loss | Not supported | Body weight tends to increase (lean + water); MK-677 stimulates appetite |
Side Effects and Safety Concerns
MK-677's side effect profile is well-characterized from clinical trials. Some effects are mild nuisances. Others are clinically significant.
The Insulin Problem
This is the single most important safety concern with MK-677 and the one most consistently glossed over in enthusiast forums. Growth hormone has inherent anti-insulin effects: it opposes insulin's action in liver and peripheral tissues, redirecting glucose metabolism. Every significant MK-677 trial has documented impaired insulin sensitivity:
Insulin and Glucose Effects Across Trials
In the Nass et al. 2-year trial, MK-677 increased fasting blood glucose by approximately 5 mg/dL on average and raised HbA1c by 0.2% compared to placebo. In the Svensson obesity study, fasting insulin increased and oral glucose tolerance worsened. Researchers terminated at least one clinical trial early due to concerns about potential congestive heart failure, a known complication of fluid retention and metabolic stress. The FDA has flagged MK-677 in the context of products containing hidden ibutamoren, citing potential risks including glucose metabolism disruption.
Who is most at risk: Anyone with pre-diabetes, insulin resistance, metabolic syndrome, type 2 diabetes, or family history of diabetes. The metabolic effects are dose-dependent and duration-dependent; longer use at higher doses compounds the risk.
Common Side Effects (from Clinical Trial Data)
| Side Effect | Frequency | Mechanism | Management |
|---|---|---|---|
| Increased appetite | Very common (most users) | Direct ghrelin receptor activation in hypothalamus | Bedtime dosing reduces daytime hunger; typically diminishes after 2-4 weeks |
| Water retention / edema | Common | GH-mediated sodium/water retention | Dose reduction; adequate potassium intake; monitor for ankle/periorbital swelling |
| Elevated fasting glucose | Common | GH's anti-insulin effect on hepatic glucose output | Glucose monitoring; limit refined carbohydrates; consider berberine/metformin under physician supervision |
| Fatigue / lethargy | Moderate (esp. first weeks) | Ghrelin-mediated sedation; blood sugar fluctuation | Bedtime dosing; start at lower dose (10-15 mg); usually resolves |
| Mild muscle pain / joint stiffness | Occasional | Rapid IGF-1 elevation; similar to GH therapy | Dose reduction; typically transient |
| Numbness / tingling (paresthesia) | Rare | Carpal-tunnel-like effect from GH-mediated soft tissue changes | Dose reduction; discontinue if persistent |
| Vivid dreams | Common (esp. bedtime dosing) | Enhanced REM sleep duration and intensity | Generally benign; some users consider this a benefit |
Theoretical Long-Term Concerns
IGF-1 and cancer risk: Chronically elevated IGF-1 has been epidemiologically associated with increased risk of certain cancers (prostate, breast, colorectal). The relationship is correlational, not proven causal, and MK-677's IGF-1 elevations are within physiological ranges (it raises levels to the young-adult range, not beyond it). However, anyone with active malignancy, cancer history, or strong family cancer predisposition should avoid chronic GH-axis stimulation until more data exists.
Cardiovascular risk: At least one MK-677 trial was halted early due to potential heart failure concerns in the study population. Fluid retention, blood pressure changes, and insulin resistance can all contribute to cardiovascular stress. This appears more relevant in elderly populations with pre-existing cardiac risk factors than in healthy younger adults, but long-term cardiovascular safety data in any population is absent.
Dosing, Timing, and Cycling
Research Dosing Context
All clinical trials used 25 mg/day as the primary dose, with some studies including 5 mg and 10 mg arms for dose-response assessment. The 25 mg dose consistently produced the strongest GH/IGF-1 elevations. The 5 mg dose showed measurable but blunted hormonal responses. No human trial has tested doses above 25 mg.
| Dose | GH/IGF-1 Response | Side Effect Profile | Context |
|---|---|---|---|
| 10-15 mg/day | Moderate GH increase; noticeable IGF-1 elevation | Mild appetite increase; minimal water retention; better glucose tolerance | Conservative starting dose; sleep benefits may be achievable at this range |
| 20-25 mg/day | Strong GH increase; ~60-73% IGF-1 elevation | Significant appetite increase; moderate water retention; glucose/insulin effects | Standard clinical trial dose; maximum studied dose |
| 25+ mg/day | Unknown (never studied in humans) | Unknown | No clinical justification; higher risk without established additional benefit |
Timing
Bedtime dosing is optimal for most users, and this is how the sleep studies administered MK-677. Bedtime dosing aligns the GH pulse amplification with the body's natural nocturnal GH surge, maximizes sleep quality benefits, and reduces the impact of appetite stimulation (since you're asleep when ghrelin receptor activation is strongest). If daytime appetite stimulation is desired (e.g., during a bulk), morning dosing is an alternative, but expect significant hunger within 1-2 hours of dosing.
Cycling Protocols
Standard Approaches
8-12 weeks on → 4-8 weeks off. The most commonly recommended cycle. Long enough for meaningful GH/IGF-1 elevation and body composition effects. The off-period allows insulin sensitivity to recover and prevents GHS-R1a receptor desensitization.
5 days on → 2 days off (weekly cycling). A more conservative approach that some practitioners recommend to maintain insulin sensitivity while still receiving GH benefits. Limited evidence for this specific pattern, but the rationale is pharmacologically sound.
Continuous low-dose (10-15 mg). Some clinicians prescribe lower-dose MK-677 continuously for anti-aging applications, with regular glucose monitoring. The Nass et al. study used 25 mg continuously for up to 2 years, but metabolic effects accumulated, suggesting that if continuous use is chosen, lower doses with glucose surveillance are prudent.
Baseline bloodwork before starting: Fasting glucose, fasting insulin, HbA1c, IGF-1, comprehensive metabolic panel. Follow-up at 4-6 weeks: Repeat fasting glucose, insulin, IGF-1. If fasting glucose rises above 100 mg/dL or insulin increases meaningfully, reduce dose or discontinue. Every 3 months during extended use: Full metabolic panel, IGF-1, liver function.
MK-677 vs. Other GH Secretagogues
| Feature | MK-677 | Ipamorelin | CJC-1295 | Sermorelin | Exogenous GH |
|---|---|---|---|---|---|
| Route | Oral | Subcutaneous | Subcutaneous | Subcutaneous | Subcutaneous |
| Mechanism | Ghrelin receptor agonist | Ghrelin receptor (selective) | GHRH receptor | GHRH receptor | Direct GH replacement |
| GH elevation | Strong, sustained | Moderate, pulsatile | Strong (with DAC) | Moderate | Strongest |
| Appetite increase | Significant | Minimal | Minimal | Minimal | Minimal |
| Insulin sensitivity | Impairs | Mild effect | Mild effect | Minimal effect | Impairs |
| Sleep effects | Significant (studied) | Anecdotal | Some reports | Some reports | Variable |
| Half-life | ~24 hours (once daily) | ~2 hours (2-3x daily) | ~30 min (no DAC) / 8 days (DAC) | ~10-20 min (daily) | Variable by formulation |
| Storage | Room temperature | Refrigeration required | Refrigeration required | Refrigeration required | Refrigeration required |
| Human data | Multiple RCTs (n=563 largest) | Limited trials | Small trials | FDA-approved (diagnostic) | FDA-approved |
| WADA status | Prohibited | Prohibited | Prohibited | Prohibited | Prohibited |
Choose MK-677 if: You strongly prefer oral administration and won't consistently inject. You prioritize sleep improvement as a primary outcome. You want the convenience of room-temperature storage and once-daily dosing. You're comfortable monitoring glucose.
Choose injectable secretagogues (Ipamorelin, CJC-1295) if: Appetite stimulation would undermine your goals (cutting/dieting). You have any insulin resistance concern. You want more targeted GH elevation without ghrelin-mediated side effects. You're comfortable with injection protocols.
Who MK-677 Is (and Isn't) For
Reasonable Candidates
Adults 35+ experiencing age-related GH decline: poor sleep quality, slow recovery, reduced body composition. Hardgainers who need appetite stimulation: MK-677's ghrelin activation is a feature, not a bug, for those who struggle to eat enough. Athletes in recovery/bulking phases: the combination of GH elevation, sleep improvement, and appetite support suits mass-gaining periods. People who are needle-averse: the oral route removes the primary barrier to GH secretagogue use. All candidates should have healthy glucose metabolism and commit to blood monitoring.
Not Appropriate For
Anyone with diabetes, pre-diabetes, or insulin resistance. MK-677 will worsen glucose control. People trying to lose weight or cut. Appetite stimulation is directly counterproductive. Competitive athletes subject to drug testing: prohibited by WADA at all times. Anyone with active cancer or cancer history: chronic IGF-1 elevation is contraindicated. People under 25: GH axis is still naturally strong; intervention unnecessary and potentially disruptive. Anyone with congestive heart failure risk.
Common Stacking Approaches
| Stack | Rationale | Notes |
|---|---|---|
| MK-677 + Ipamorelin | Dual GH pathway stimulation (ghrelin + GHRP receptor); potentially additive GH elevation | May exacerbate insulin effects; monitor glucose closely; reduce MK-677 dose to 10-15 mg |
| MK-677 + CJC-1295 (no DAC) | Ghrelin pathway + GHRH pathway = two distinct GH release mechanisms | Popular "blast" combination; CJC provides pulse initiation, MK-677 amplifies; cycle 8-12 weeks |
| MK-677 + BPC-157 | GH elevation + tissue repair; targets both systemic growth and local healing | Common injury recovery stack; no known interaction concerns |
| MK-677 + Testosterone (TRT) | GH + anabolic hormone synergy for body composition | Requires physician oversight; additive fluid retention; monitor hematocrit and glucose |
| MK-677 + Berberine/Metformin | Countering MK-677's insulin resistance with glucose-sensitizing agents | Some practitioners routinely co-prescribe; pharmacological rationale is sound but unstudied as a combination |
Legal and Regulatory Status
| Jurisdiction | Status | Details |
|---|---|---|
| United States | Legal gray area | Not a controlled substance; not FDA-approved for any indication; sold as "research chemical." FDA has taken enforcement action against products containing hidden ibutamoren marketed as supplements (2024). |
| WADA / Sports | Prohibited | Banned at all times under S2 (Peptide Hormones, Growth Factors) as a growth hormone secretagogue. Detectable in blood and urine. |
| Australia | Prescription only | Classified as Schedule 4; illegal to possess without prescription. |
| European Union | Varies by country | Generally not approved; availability varies. Often sold as research material. |
| Clinical pipeline | Active (as LUM-201) | Lumos Pharma completed Phase II trials for pediatric GH deficiency under the name LUM-201. Still investigational. |
Frequently Asked Questions
Is MK-677 a steroid or a SARM?
Do I need PCT (post-cycle therapy) after MK-677?
Will MK-677 help me lose fat?
Can I take MK-677 long-term?
How long until I notice effects?
Does MK-677 show up on drug tests?
Is MK-677 safe for women?
How does MK-677 compare to actual GH injections?
Key Takeaways
MK-677 is the most convenient and well-studied oral growth hormone secretagogue available. It reliably increases GH and IGF-1 to young-adult levels, demonstrably improves sleep architecture, produces modest gains in fat-free mass, and reverses diet-induced catabolism. However, the clinical data does not support several of its most popular claimed benefits: it did not improve strength or physical function in a 2-year RCT, it did not reduce fat mass, and it did not slow cognitive decline in the largest trial ever conducted.
The insulin resistance problem is real and dose/duration-dependent. Anyone considering MK-677 should get baseline metabolic bloodwork, start at 10-15 mg (not the full 25 mg trial dose), dose at bedtime, cycle on and off, and monitor glucose at regular intervals. The strongest use case may be sleep optimization, an effect that cascades into recovery, mood, and body composition through improved sleep quality rather than direct anabolic action.
For those who are injection-averse and want GH-axis support, MK-677 remains the only oral option with multi-year human data. For those who can inject, peptides like Ipamorelin offer a cleaner side-effect profile without the appetite stimulation and insulin concerns. The right choice depends on your goals, your metabolic baseline, and your willingness to monitor bloodwork.
This article is for educational and informational purposes only. It is not medical advice. MK-677 (ibutamoren) is not FDA-approved for any indication and is classified as an investigational drug. It is prohibited in sport by WADA. Do not use MK-677 without consulting a qualified healthcare provider. Individual responses vary, and the metabolic side effects documented in clinical trials (insulin resistance, glucose elevation) can pose real health risks, particularly in metabolically vulnerable populations. Always prioritize safety and medical oversight.
References
Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PMC2757071.
Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320-325. PMID: 9467534.
Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278-286. PMID: 9349662.
Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, et al. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab. 1996;81(8):2776-2782. PMID: 8768828.
Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-369.
Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res. 1999;14(7):1182-1188.
Murphy MG, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2001;86(3):1116-1125.
Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708. PMID: 19015485.
Codner E, Cassorla F, Tiulpakov AN, et al. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther. 2001;70(1):91-98.
Chapman IM, Pescovitz OH, Murphy G, et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. J Clin Endocrinol Metab. 1997;82(10):3455-3463.
Liu H, Sun D, Myasnikov A, et al. Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nat Commun. 2021;12:6410.